全文获取类型
收费全文 | 14580篇 |
免费 | 1524篇 |
国内免费 | 385篇 |
学科分类
医药卫生 | 16489篇 |
出版年
2024年 | 9篇 |
2023年 | 309篇 |
2022年 | 269篇 |
2021年 | 586篇 |
2020年 | 685篇 |
2019年 | 760篇 |
2018年 | 758篇 |
2017年 | 706篇 |
2016年 | 620篇 |
2015年 | 551篇 |
2014年 | 870篇 |
2013年 | 1056篇 |
2012年 | 805篇 |
2011年 | 833篇 |
2010年 | 708篇 |
2009年 | 683篇 |
2008年 | 689篇 |
2007年 | 650篇 |
2006年 | 698篇 |
2005年 | 629篇 |
2004年 | 516篇 |
2003年 | 478篇 |
2002年 | 401篇 |
2001年 | 359篇 |
2000年 | 272篇 |
1999年 | 231篇 |
1998年 | 195篇 |
1997年 | 158篇 |
1996年 | 137篇 |
1995年 | 110篇 |
1994年 | 135篇 |
1993年 | 75篇 |
1992年 | 111篇 |
1991年 | 69篇 |
1990年 | 41篇 |
1989年 | 52篇 |
1988年 | 41篇 |
1987年 | 33篇 |
1986年 | 31篇 |
1985年 | 36篇 |
1984年 | 20篇 |
1983年 | 16篇 |
1982年 | 23篇 |
1981年 | 16篇 |
1980年 | 12篇 |
1979年 | 15篇 |
1978年 | 6篇 |
1977年 | 8篇 |
1976年 | 6篇 |
1974年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
22.
Jessica Roberts MBBS Jason Powell MBBS MClinRes PhD MRCS Jacob Begbie MBBS MRes Gerard Siou MBBS MD FRCS Claire McLarnon MBBS MSc FRCS Andrew Welch MBBS FRCS Michael McKean MBChB MD FRCPCH Mathew Thomas MBChB MRCPCH PhD Anne-Marie Ebdon MBBS MRCPCH FRACP Samantha Moss MBBS MRCPCH MD Rachel S. Agbeko MSc MD PhD FRCPCH FFICM Jonathan H. Smith MBChB MRCP FRCA Malcolm Brodlie MB ChB PhD MRCPCH Christopher O'Brien MBBS FRCPCH Steven Powell MBBS MSc FRCS 《The Laryngoscope》2020,130(5):E375-E380
23.
24.
25.
26.
Renaud Snanoudj Nassim Kamar Elisabeth Cassuto Sophie Caillard Marie Metzger Pierre Merville Antoine Thierry Isabelle Jollet Philippe Grimbert Dany Anglicheau Marc Hazzan Gabriel Choukroun Bruno Hurault De Ligny Bénedicte Janbon Vincent Vuiblet Anne Devys Yann Le Meur Michel Delahousse Jean-Luc Taupin 《Kidney international》2019,95(6):1471-1485
27.
R. Watson T. Kozlowski V. Nickeleit J. T. Woosley J. L. Schmitz S. L. Zacks J. H. Fair D. A. Gerber K. A. Andreoni 《American journal of transplantation》2006,6(12):3022-3029
Antibody-mediated rejection (AMR) after liver transplantation is recognized in ABO incompatible and xeno-transplantation, but its role after ABO compatible liver transplantation is controversial. We report a case of ABO compatible liver transplantation that demonstrated clinical, serological and histological signs of AMR without evidence of concurrent acute cellular rejection. AMR with persistently high titers of circulating donor specific antibodies resulted in graft injury with initial centrilobular hepatocyte necrosis, fibroedematous portal expansion mimicking biliary tract outflow obstruction, ultimately resulting in extensive bridging fibrosis. Immunofluorescence microscopy demonstrated persistent, diffuse linear C4d deposits along sinusoids and central veins. Despite intense therapeutic intervention including plasmapheresis, IVIG and rituximab, AMR led to graft failure. We present evidence that an antibody-mediated alloresponse to an ABO compatible liver graft can cause significant graft injury independent of acute cellular rejection. AMR shows distinct histologic changes including a characteristic staining profile for C4d. 相似文献
28.
S. Nishida J. J. Gaynor N. Nakamura F. Butt H. G. Illanes J. Kadono G. W. Neff D. M. Levi J. I. Moon G. Selvaggi T. Kato P. Ruiz A. G. Tzakis J. R. Madariaga 《American journal of transplantation》2006,6(1):140-149
A retrospective study of 1058 liver transplant recipients was performed to determine: (i) the incidence, etiology, timing, clinical features and treatment of refractory ascites (RA), (ii) risk factors for RA development, (iii) predictors of RA disappearance, (iv) predictors of survival following RA and (v) the impact of RA on patient survival. Sixty-two patients (5.9%) developed RA and its disappearance occurred in 27/62 cases. Patients having hepatitis C virus (HCV) had a significantly higher hazard rate of developing RA (p < 0.00001). No other baseline characteristic was associated with RA. Cox stepwise regression analysis of the hazard rate of RA disappearance found two significant factors: HCV recurrence as the reason for developing RA implied a poorer outcome (p = 0.006), whereas an unknown reason implied a favorable outcome (p = 0.02). In addition, survival following RA was significantly poorer among patients having bacterial peritonitis or HCV recurrence. Finally, the mortality rate was significantly (nearly 8.6 times) higher in patients following RA development while it was ongoing (p < 0.00001); however, if the RA disappeared, then the additional risk of death also disappeared. This study illustrates the importance of developing an optimal treatment strategy to (i) effectively treat RA if it develops and (ii) prevent hepatitis C recurrence. 相似文献
29.
It is important to determine when to use and when to avoid calcineurin inhibitors (CNIs). CNIs are associated with kidney dysfunction in some, but not all, transplant recipients. CNI-sparing protocols have their own drug-specific limitations. Two major clinical series suggest the benefit of routine CNI-sparing approaches, but our review suggests weaknesses in both. Ongoing studies are needed to determine which subgroups of recipients will benefit from CNIs. 相似文献
30.
A. A. Vo M. Toyoda A. Peng S. Bunnapradist M. Lukovsky S. C. Jordan 《American journal of transplantation》2006,6(10):2384-2390
Here we retrospectively examine the efficacy of two antibody induction regimens using Zenapax or Thymoglobulin in patients with positive complement-dependent cytotoxicity crossmatches (CDC-CMXs) desensitized with IVIG (intravenous immunoglobulin). Between January 1999 and March 2005, 97 patients with (+) CDC-CMXs received kidney transplants (43 deceased donors/54 living donors). All patients received at least 2 g/kg IVIG (maximum four doses) until an acceptable CMX was obtained. Patients were divided into two groups: 1. IVIG + Zenapax (n = 58), 2. IVIG + Thymoglobulin (n = 39). A total of 94% of patients in Group 1 and 84% in G2 have at least 2 years of follow up. Patient and graft survival was 96%/84% in Group 1 and 100%/90% in Group 2, p = NS. The number and severity of AR episodes were similar (36% Group 1 vs. 31% Group 2, p = NS) as was the incidence of C4d (+) antibody-mediated rejection (AMR) (Banff Grade II/III) (22% Group 1 vs. 21% Group 2). Mean serum creatinines (SCrs) at 24 months were similar (Group 1: 1.4 +/- 0.7 vs. G2: 1.5 +/- 0.7 mg/dL). Induction therapy with Zenapax or Thymoglobulin results in excellent patient, graft survival and graft function at 2 years. There was no increased risk of viral infections or malignancies with either agent. Neither agent was effective in reducing the incidence of AMR. 相似文献